Special Feature Article
Review Journal “Penetration”
Preclinical scientific rationale for High-Dose Levofloxacin Dose Schedule
What is the scientific rationale for using 750mg levofloxacin in CAP?
What are the PK/PD differences between the 500mg and 750mg dose?
How do the PK/PD features of the 750mg dose result in microbiological effects?
What clinical benefits are derived from the PK/PD features of the 750 mg dose?
Results of Clinical studies investigating High-Dose Levofloxacin
Summary of clinical studies investigating 750mg dose
Comparison between 750mg levofloxacin and other FQ in CAP
Comparison between 750mg levofloxacin and other non-FQ comparator agents in CAP.
Clinical Advantages Associated with High-Dose Levofloxacin in CAP
What effect does high-dose levofloxacin have on duration of therapy?
Does the High-Dose schedule have an effect on the development of resistance?
Effect of High-Dose therapy on Compliance
Advantages of Shorter Duration of IV therapy
Who should be treated with high-dose levofloxacin?
Safety Issues Relating to High-Dose Levofloxacin
What is the safety profile of the 750mg schedule?
Are there any patient groups in whom high-dose therapy is contraindicated?
Differences in the safety profile of 750mg levofloxacin versus other FQ?
Non-Clinical Advantages of High-Dose Levofloxacin in CAP
Cost-effectiveness benefits of the high-dose strategy
©1998-2007 BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.